Dataset Information

Platycodin D attenuates alcohol-associated fatty liver disease by suppressing TLR4–NF-κB and activating PPAR signaling

ABSTRACT:

Alcohol-associated fatty liver disease (AFLD) is driven by ethanol-induced metabolic dysregulation and hepatic inflammation, with gut dysbiosis and endotoxin-triggered innate immune activation implicated in disease progression. Platycodin D (PD), a triterpenoid saponin from Platycodon grandiflorum, has been reported to have antioxidant and immunomodulatory activities, but its efficacy and mechanisms in AFLD remain unclear. We hypothesized that PD alleviates AFLD by suppressing TLR4/NF-κB signaling, activating PPAR pathways, and remodeling gut microbiota and hepatic metabolites.

INSTRUMENT(S): Liquid Chromatography MS - positive - hilic, Liquid Chromatography MS - negative - hilic

PROVIDER: MTBLS13658 | MetaboLights | 2026-01-12

REPOSITORIES: MetaboLights

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	a_MTBLS13658_LC-MS_negative_hilic_metabolite_profiling.txt	Txt
	a_MTBLS13658_LC-MS_positive_hilic_metabolite_profiling.txt	Txt
	i_Investigation.txt	Txt
	m_MTBLS13658_LC-MS_negative_hilic_metabolite_profiling_v2_maf.tsv	Tabular
	m_MTBLS13658_LC-MS_positive_hilic_metabolite_profiling_v2_maf.tsv	Tabular

Items per page:

1 - 5 of 6

Similar Datasets

Project description:Post-translational acetylation of proteins at lysine side chains by the central metabolite acetyl-CoA, is a crucial regulator of proteostasis. Ethanol metabolism in the liver induces protein acetylation and disrupts hepatic substrate metabolism. While acetylation can influence gene transcription, enzyme activity, and stability of proteins, the role of ethanol-induced acetylation in hepatic metabolism is still unclear. We used a 2H2O-based metabolic labeling approach to investigate the impact of ethanol-induced acetylation on liver metabolism in a murine model of chronic ethanol-induced liver injury. Mice were fed an ethanol containing diet for 25 days; liver proteins and acetylation patterns were monitored during the final 21 days of 2H2O labeling. The proteome, acetylome, and targeted metabolic profiling were conducted to evaluate ethanol-induced alterations in hepatic metabolism. Ethanol consumption induced hepatic steatosis, inflammation, and oxidative stress. It led to reduced turnover of mitochondrial proteins and increased turnover of cytosolic stress response proteins and metabolic enzymes. Ethanol elevated acetylation levels of mitochondrial metabolic enzymes and nuclear histones, with no significant changes in the cytosol. Acetylation stabilized mitochondrial proteins but destabilized histones. Ethanol-induced reduced mitochondrial protein turnover, linked to increased acetylation, led to hepatic protein accumulation. Impaired proteasomal and lysosomal degradation contributed to alcohol-induced hepatic proteopathy. These changes were associated with altered levels of acyl-CoAs and acyl-carnitines, amino acids, and tricarboxylic acid (TCA) cycle intermediates, reflecting impaired fatty acid oxidation, nitrogen disposal and citric acid cycle activities. In conclusion, ethanol-induced alterations in acetylome dynamics could modify hepatic substrate metabolism and contribute to liver injury in alcohol-associated liver disease through acetylation-dependent epigenetic changes and the regulation of metabolic enzymes.

Project description:Background: Exposure to pollutants including the ubiquitous ‘forever chemical’, Perfluorooctane sulfonate (PFOS) has increasingly been associated with metabolic dysfunction-associated steatotic liver disease (MASLD). Recent epidemiological evidence has identified associations between Per- and polyfluoroalkyl substances (PFAS) exposure and increased liver injury in alcohol consumers, suggesting potential interactions between these exposures. However, the intersection of pollutant exposures and alcohol-associated liver disease (ALD) is not well studied. We hypothesize that pollutants may disrupt hepatic metabolism to modify ALD severity. Recently, we developed a two-hit (ethanol plus pollutant) mouse model, enabling testing of this hypothesis. Here, we elucidate the metabolic and disease-modifying effects of PFOS in this model. Methods: Male C57BL/6J mice were fed isocaloric control or 5% Ethanol (EtOH) Lieber-DeCarli diet for 15 days. From day 6 of feeding, mice were concurrently gavaged with 1 mg/kg PFOS or 2% tween-80 vehicle for 10 days, followed by a 5 g/kg EtOH binge dose and euthanized 5-6 hours later. Results: Approximately 60% of the administered PFOS dose accumulated in liver. PFOS exacerbated EtOH-induced hepatic steatosis and was associated by higher levels of plasma very low-density lipoprotein (vLDL) and alanine aminotransferase (ALT). PFOS upregulated hepatic ethanol-metabolizing enzymes and lowered blood alcohol levels. Ingenuity Pathway Analysis (IPA) Top Toxicity Functions/Lists associated with hepatic gene expression following PFOS co-exposure in EtOH-fed mice included: fatty acid metabolism and liver steatosis; nuclear receptor activation, cytochrome P450, and reactive oxygen species (ROS); apoptosis; liver fibrosis; and hepatocellular carcinoma (HCC). GO/KEGG analyses similarly revealed enrichment in fatty acid, xenobiotic, alcohol, or glutathione metabolic processes; and Peroxisome proliferator-activated receptor (PPAR) signaling. PFOS upregulated hepatic expression of several nuclear receptors (e.g., Pparα, Car, and Pxr) and their P450 target genes (e.g., Cyp4a10, Cyp2b10, and Cyp3a11) by RT-PCR or Western blot, confirming key IPA predictions. Conclusions: PFOS is a metabolism disrupting chemical that worsened ALD severity. PFOS activated hepatic nuclear receptors and enriched hepatic transcriptional pathways associated with steatosis, xenobiotic metabolism, oxidative stress, cell death, fibrosis, and HCC. These data demonstrate a novel mechanism whereby PFOS exacerbates ALD through coordinated dysregulation of lipid homeostasis and liver injury, potentially mediated by nuclear receptor activation. The identification of PFOS as an ALD risk modifier highlight the critical need to evaluate environmental pollutants as potential contributors to liver disease progression in vulnerable populations. More data are required on environmental pollution as a disease modifying factor in ALD.

Dataset Information

Platycodin D attenuates alcohol-associated fatty liver disease by suppressing TLR4–NF-κB and activating PPAR signaling

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets